Octapharma USA Cross-specialty Advisory Board 2023

Welcome to the Octapharma Cross Specialty Advisory Board's Science Hub Page

Please note that access to the content on this page is reserved for participants of our event.

We extend a warm welcome to this exclusive webpage dedicated to the Octapharma Cross Specialty Advisory Board, scheduled for September 14 - 16, 2023.

Here, you will find a wealth of resources, including key publications related to Octapharma therapies, that may be referenced throughout the meeting. These materials are curated to enhance your experience and provide valuable insights.

Thank you for visiting, and we anticipate a productive and enlightening engagement during the event.

Publications on fibrinogen concentrate

• Callum J, Farkouh ME, Scales DC, Heddle NM, Crowther M, Rao V, Hucke HP, Carroll J, Grewal D, Brar S, Bussières J, Grocott H, Harle C, Pavenski K, Rochon A, Saha T, Shepherd L, Syed S, Tran D, Wong D, Zeller M, Karkouti K; FIBRES Research Group. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA. 2019 Nov 26;322(20):1966-1976. doi: 10.1001/jama.2019.17312. PMID: 31634905; PMCID: PMC6822637. [PubMed]

• Roy A, Stanford S, Nunn S, Alves S, Sargant N, Rangarajan S, Smith EA, Bell J, Dayal S, Cecil T, Tzivanakis A, Kruzhkova I, Solomon C, Knaub S, Moran B, Mohamed F. Efficacy of fibrinogen concentrate in major abdominal surgery - A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei. J Thromb Haemost. 2020 Feb;18(2):352-363. doi: 10.1111/jth.14665. Epub 2019 Nov 26. PMID: 31654548; PMCID: PMC7027898. [PubMed]

• Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Subramanian K, D'Souza F, Viswabandya A, Hoorfar H, Schwartz BA, Solomon C, Knaub S, Peyvandi F. Fibrinogen concentrate for treatment of bleeding and surgical prophylaxis in congenital fibrinogen deficiency patients. J Thromb Haemost. 2020 Apr;18(4):815-824. doi: 10.1111/jth.14727. Epub 2020 Jan 21. PMID: 31885190; PMCID: PMC7187153. [PubMed]

Abstract on Prothrombin Complex Concentrate

• Ravi Sarode, Stephan Maack, Cristina Solomon, Sigurd Knaub, Sam Schulman; A Phase 3, Randomized, Double-Blinded Study of Four-Factor Prothrombin Complex Concentrate in Patients with Acute Major Bleeding on Direct Oral Anticoagulant Therapy with Factor Xa Inhibitor: The Lex-210 Study. Blood 2021; 138 (Supplement 1): 3235. doi: https://doi.org/10.1182/blood-2021-152697

Publication on SD treated plasma

• Stensballe J, Ulrich AG, Nilsson JC, Henriksen HH, Olsen PS, Ostrowski SR, Johansson PI. Resuscitation of Endotheliopathy and Bleeding in Thoracic Aortic Dissections: The VIPER-OCTA Randomized Clinical Pilot Trial. Anesth Analg. 2018 Oct;127(4):920-927. doi: 10.1213/ANE.0000000000003545. PMID: 29863610; PMCID: PMC6135474. [PubMed]

Publications on Antithrombin deficiency

• Ehrhardt JD Jr, Boneva D, McKenney M, Elkbuli A. Antithrombin Deficiency in Trauma and Surgical Critical Care. J Surg Res. 2020 Dec;256:536-542. doi: 10.1016/j.jss.2020.07.010. Epub 2020 Aug 13. PMID: 32799002. [PubMed]

• Hart C, Rott H, Heimerl S, Linnemann B. Management of Antithrombin Deficiency in Pregnancy. Hamostaseologie. 2022 Oct;42(5):320-329. doi: 10.1055/a-1841-0399. Epub 2022 Nov 2. PMID: 36323279. [PubMed]

• Roberts JC, von Drygalski A, Zhou JY, Rodgers GM, Ansteatt K, Tarantino MD. Five Challenging Cases of Hereditary Antithrombin Deficiency Characterized by Thrombosis or Complicated Pregnancy. J Blood Med. 2022 Oct 21;13:611-618. doi: 10.2147/JBM.S365996. PMID: 36303565; PMCID: PMC9595055. [PubMed]

Publication on Dermatomyositis

• Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovský J, Beckmann I, Clodi E, Bugrova O, Dankó K, Ernste F, Goyal NA, Heuer M, Hudson M, Hussain YM, Karam C, Magnolo N, Nelson R, Pozur N, Prystupa L, Sárdy M, Valenzuela G, van der Kooi AJ, Vu T, Worm M, Levine T; ProDERM Trial Group. Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022 Oct 6;387(14):1264-1278. doi: 10.1056/NEJMoa2117912. PMID: 36198179. [PubMed]

Publications on CIDP

• Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E; ProCID Investigators. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022 Apr 29;145(3):887-896. doi: 10.1093/brain/awab422. PMID: 35038723; PMCID: PMC9050528. [PubMed]

• Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E; ProCID Investigators. Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study. Drug Saf. 2023 Sep;46(9):835-845. doi: 10.1007/s40264-023-01326-z. Epub 2023 Jun 28. PMID: 37378806; PMCID: PMC10442284. [PubMed]

Publications on subcutaneous immunoglobulin therapy

• Kobayashi RH, Gupta S, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Turpel-Kantor E, Litzman J. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies. Front Immunol. 2019 Feb 4;10:40. doi: 10.3389/fimmu.2019.00040. Erratum in: Front Immunol. 2022 Dec 20;13:1110388. PMID: 30778345; PMCID: PMC6369354. [PubMed]

• Kobayashi RH, Litzman J, Melamed I, Mandujano JF, Kobayashi AL, Ritchie B, Geng B, Atkinson TP, Rehman S, Höller S, Turpel-Kantor E, Kreuwel H, Speer JC, Gupta S. Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies. Clin Exp Immunol. 2022 Dec 15;210(2):91-103. doi: 10.1093/cei/uxac092. PMID: 36208448; PMCID: PMC9750824. [PubMed]

• Gupta S, DeAngelo J, Melamed I, Walter JE, Kobayashi AL, Bridges T, Sublett JW, Bernstein JA, Koterba A, Manning M, Maltese J, Hoeller S, Turpel-Kantor E, Kreuwel H, Kobayashi RH. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens. J Clin Immunol. 2023 Aug;43(6):1414-1425. doi: 10.1007/s10875-023-01509-4. Epub 2023 May 9. PMID: 37160610; PMCID: PMC10169187. [PubMed]

Publication on PANS

• Melamed I, Kobayashi RH, O'Connor M, Kobayashi AL, Schechterman A, Heffron M, Canterberry S, Miranda H, Rashid N. Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome. J Child Adolesc Psychopharmacol. 2021 Mar;31(2):118-128. doi: 10.1089/cap.2020.0100. Epub 2021 Feb 18. PMID: 33601937; PMCID: PMC7984935. [PubMed]

Publication on primary infection prophylaxis in CLL

• Oliver Cornely, Anthony Mato, Tadeusz Robak, Sibylle Mellinghoff, Tatiana Lavrova, The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIG) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia- Study Design, Blood, Volume 136, Supplement 1,2020,Pages 20-21,ISSN 0006-4971, https://doi.org/10.1182/blood-2020-136898.

Publications on hemophilia A

• Liesner RJ, Abraham A, Altisent C, Belletrutti MJ, Carcao M, Carvalho M, Chambost H, Chan AKC, Dubey L, Ducore J, Gattens M, Gresele P, Gruel Y, Guillet B, Jimenez-Yuste V, Kitanovski L, Klukowska A, Lohade S, Mancuso ME, Oldenburg J, Pavlova A, Pollio B, Sigaud M, Vdovin V, Vilchevska K, Wu JKM, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thromb Haemost. 2021 Nov;121(11):1400-1408. doi: 10.1055/s-0040-1722623. Epub 2021 Feb 13. PMID: 33581698; PMCID: PMC8570909. [PubMed]

• Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR; sippet study group. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 Jan;16(1):39-43. doi: 10.1111/jth.13888. Epub 2017 Nov 16. PMID: 29080391. [PubMed]

• Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F; SIPPET Study Group. Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood. 2017 Oct 12;130(15):1757-1759. doi: 10.1182/blood-2017-06-791756. Epub 2017 Aug 2. PMID: 28768627. [PubMed]

Publication on von Willebrand disease

• Robert F. Sidonio, Jr., Ana Boban, Leonid Dubey, Adlette Inati, Csongor Kiss, Toshko Lissitchkov, Dzmitry Novik, Elina Peteva, Ali T. Taher, Margarita Arkadevna Timofeeva, Kateryna V. Vilchevska, Vladimir Vdovin, Sylvia Werner, Sigurd Knaub, Claudia Khayat; Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease. Blood 2022; 140 (Supplement 1): 8438–8439. doi: https://doi.org/10.1182/blood-2022-162358

We invite you to explore the other exciting Science Hub pages available via the main navigation options at the top of this page.